# Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema

> **NCT05699759** · PHASE1 · COMPLETED · sponsor: **Michelle Abou-Jaoude** · enrollment: 1 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** K8

## Key facts

- **NCT ID:** NCT05699759
- **Lead sponsor:** Michelle Abou-Jaoude
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-04
- **Primary completion:** 2024-06-20
- **Final completion:** 2024-06-20
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699759, "Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05699759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*